Medtronic deep brain stimulation software earns FDA nod

Activa RC neurostimulatior for deep brain stimulation--Courtesy of Medtronic

The FDA cleared Medtronic’s StealthStation software to help in the planning and placement of leads for deep brain stimulation, the company announced Monday.

In Medtronic’s deep brain stimulation therapy, a small neurostimulator is implanted under the skin of the chest. The stimulation is delivered via leads that are implanted in the brain and connected to the implant. A clinician uses an external programmer to set and adjust the stimulation.

The StealthStation Cranial Software is integrated with Medtronic’s O-arm imaging system in a solution that offers preoperative planning and intraoperative imaging for lead placement procedures, the company said in a statement.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"The new StealthStation software works seamlessly with O-arm to give me a single solution for pre-operative planning and real-time 3D imaging of the brain in the OR, and that streamlines my workflow for DBS lead placement," said Dr. Jonathan Carlson, a neurosurgeon at Providence Spokane Neuroscience Institute, in the statement.

More than 140,000 patients worldwide have received a Medtronic DBS neurostimulator. The treatment targets specific symptoms by delivering mild electrical stimulation to the brain. It is used to ease symptoms of essential tremor, Parkinson’s disease and dystonia.

In August, Medtronic’s SureTune 2 software for DBS therapy scored a CE mark. It offers physicians patient-specific visualizations to help them “tune,” or choose the most appropriate settings for, a patient’s stimulation.

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.